Searched for
TAKEDA PHARMACEUTICAL CO
Trump tariffs on chips and drugs would hit U.S. allies in AsiaU.S. President Donald Trump plans to introduce tariffs on imported computer chips, pharmaceuticals, and steel to encourage domestic manufac...- Japan shares end lower on vaccine delay, caution ahead of earnings seasonThe Nikkei 225 Index ended down 0.96% at 28,546.18 points, with consumer cyclicals, energy and materials makers leading the decline. The br...
- Nikkei ends at 30-year high as drug makers rally on Covid-19 treatment newsThe Nikkei index ended 0.09 per cent higher at 28,164.34 after recovering from early declines, while the broader Topix index edged up 0.16 ...
- Japan shares end near three-decade high after Trump signs stimulus billThe Nikkei 225 Index ended up 0.74% at 26,854.03, just shy of a 30-year high hit last week. The broader Topix rose 0.54% to 1,788.04.
- Chief of Asia's largest pharmaceutical company urges transparency in virus vaccine rolloutTakeda, one of the world's biggest pharmaceutical companies, is not developing its own vaccine but has contracts with several firms to dist...
- Japan shares close at 29-year high on GDP rebound, vaccine raceThe Nikkei 225 Index ended 2.05% firmer at 25,906.93, its highest close since June 1991. The broader Topix gained 1.68% to 1,731.81.
- Japan stocks fall as risks on several fronts unsettle investorsThe biggest underperformers among the top 30 core Topix names were venture capitalist SoftBank Group Corp, down 2.08%, followed by drugs ma...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- Nikkei drops tracking Wall Street losses on Powell's dour growth viewThe benchmark Nikkei average declined 1.7 per cent to 19,914.78, moving away from a two-month high hit earlier this week.
- Nikkei falls to 15-month low as Fed outlook knocks sentimentTakeda had sunk to a six-year low of 3,498 yen on Wednesday after a ratings downgrade by Moody's.
- Valeant to sell $2.1 billion in assets to pay down debtSkincare is the largest category in the cosmetics industry, accounting for more than one-third of the global market, according to data trac...
- Japanese companies make cautious return to Indian pharma marketOther drug companies whose acquisition went southwards included Mitsui & Co, which acquired a significant stake in Arch Pharma.
- Rashmi Barbhaiya, co-founder of Advinus Therapeutics resigns from the post of managing directorRashmi Barbhaiya, who co-founded Tata group-promoted pharmaceutical research company Advinus Therapeutics, has stepped down from the post o...
- Nikkei rebounds as Wall St gains, retreat in yen helps sentimentThe Nikkei share average rose 1% to 19,226.92 points by midmorning, but looked set to fall 1.2% for the week.
- Sun Pharma arm to buy Takeda's US-based generics subsidiary URL PharmaSun Pharmaceutical Industries today said its arm Caraco Pharma will buy Japanese drug maker Takeda Pharmaceuticals' US-based generics subsi...
- Japan's Takeda eyes Lupin, Cipla pharma business; shares surge in morning tradeShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Cipla, Lupin shares surge in morning trade on boursesShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Japan's Takeda eyes Lupin, Cipla pharma businessTakeda, Japan's largest pharmaceutical firm, has begun talks with two of India's biggest companies for purchasing either of their pharma bu...
- Takeda joins Toshiba in $16 bn cross-border deals to overcome slumpTakeda and Toshiba to buy Nycomed and Landis+Gyr for $13.7 billion and $2.3 billion, respectively.
- Japan's Takeda in $8.8 billion bid for US biotech firmJapan's Takeda Pharmaceutical Co has agreed to pay about $8.8 billion for US biotech company Millennium Pharmaceuticals Inc, the two firms ...
Load More
